1,082
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study

, , , , &
Pages 543-549 | Received 04 May 2014, Accepted 03 Sep 2014, Published online: 22 Mar 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Hai-Ping Zhang, Shu-Yu Li, Jian-Ping Wang & Jun Lin. (2018) Clinical significance and biological roles of cyclins in gastric cancer. OncoTargets and Therapy 11, pages 6673-6685.
Read now

Articles from other publishers (12)

Ahmad S. Abdelrazek, Khaled Ghoniem, Mohamed E. Ahmed, Vidhu Joshi, Ahmed M. Mahmoud, Nader Saeed, Nazih Khater, Mohammed S. Elsharkawy, Ahmed Gamal, Eugene Kwon & Ayse Tuba Kendi. (2023) Prostate Cancer: Advances in Genetic Testing and Clinical Implications. Uro 3:2, pages 91-103.
Crossref
Pan Xu, Aoran Luo, Chuan Xiong, Hong Ren, Liang Yan & Qiang Luo. (2022) SCUBE3 downregulation modulates hepatocellular carcinoma by inhibiting CCNE1 via TGFβ/PI3K/AKT/GSK3β pathway. Cancer Cell International 22:1.
Crossref
YI DONG, LIANBO ZHANG, XIN GUAN, TAO LIU & LIMIN ZHOU. (2021) Long noncoding RNA LINC02568 sequesters microRNA-874-3p to facilitate malignancy in breast cancer cells via cyclin E1 overexpression. Oncology Research 29:4, pages 291-303.
Crossref
Khalid El Bairi, Ouissam Al Jarroudi & Said Afqir. 2021. Ovarian Cancer Biomarkers. Ovarian Cancer Biomarkers 59 133 .
Ran Wei, Pichaya Thanindratarn, Dylan C. Dean, Francis J. Hornicek, Wei Guo & Zhenfeng Duan. (2020) Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma. Journal of Orthopaedic Research 38:9, pages 1952-1964.
Crossref
Zhen Yuan, Liang Zhong, Dongdong Liu, Juanjuan Yao, Junmei Liu, Pengqiang Zhong, Shifei Yao, Yi Zhao, Lianwen Li, Min Chen, Lu Liu & Beizhong Liu. (2019) MiR-15b regulates cell differentiation and survival by targeting CCNE1 in APL cell lines. Cellular Signalling 60, pages 57-64.
Crossref
Marijn A Vermeulen, Shusma C Doebar, Carolien H M van Deurzen, John W M Martens, Paul J van Diest & Cathy B Moelans. (2018) Copy number profiling of oncogenes in ductal carcinoma in situ of the male breast. Endocrine-Related Cancer 25:3, pages 173-184.
Crossref
Hanna Fredholm, Kristina Magnusson, Linda S. Lindström, Nicholas P. Tobin, Henrik Lindman, Jonas Bergh, Lars Holmberg, Fredrik Pontén, Jan Frisell & Irma Fredriksson. (2017) Breast cancer in young women and prognosis: How important are proliferation markers?. European Journal of Cancer 84, pages 278-289.
Crossref
Cecilia Ahlin, Claudia Lundgren, Elin Embretsén-Varro, Karin Jirström, Carl Blomqvist & M. -L. Fjällskog. (2017) High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. Breast Cancer Research and Treatment 164:3, pages 667-678.
Crossref
Mamoru Takada, Shigenori Nagai, Masayuki Haruta, Ryuichi P. Sugino, Katsunori Tozuka, Hiroyuki Takei, Fumie Ohkubo, Kenichi Inoue, Masafumi Kurosumi, Masaru Miyazaki, Aiko Sato-Otsubo, Yusuke Sato, Seishi Ogawa & Yasuhiko Kaneko. (2017) BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy . Genes, Chromosomes and Cancer 56:5, pages 405-420.
Crossref
I.A. McNeish. (2016) Prognostic pathways in early-stage ovarian cancer: can gene expression transcend histological subtype?. Annals of Oncology 27:8, pages 1366-1368.
Crossref
Emiliano Cocco, Salvatore Lopez, Jonathan Black, Stefania Bellone, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Carlton L Schwab, Gulden Menderes, Luca Zammataro, Natalia Buza, Pei Hui, Serena Wong, Siming Zhao, Yalai Bai, David L Rimm, Elena Ratner, Babak Litkouhi, Dan-Arin Silasi, Masoud Azodi, Peter E Schwartz & Alessandro D Santin. (2016) Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal of Cancer 115:3, pages 303-311.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.